Long Noncoding RNA PART1 Promotes Hepatocellular Carcinoma Progression via Targeting miR-590-3p/HMGB2 Axis

Introduction: In East Asia, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancer types. Long noncoding RNA (lncRNA) prostate androgen-regulated transcript 1 (PART1) was reported to play crucial roles in regulating cancer progression. However, roles and mechanisms of action of PART1 in hepatocellular carcinoma (HCC) still remain unknown.

Methods: Quantitative real-time polymerase chain reaction (RT-qPCR) method was used to detect the PART1 expression level in HCC cells. Cell proliferation, colony formation, and transwell invasion assays were performed to investigate the biological roles of PART1 on HCC cell behaviors. Bioinformatic analysis methods were performed to analyze connections of microRNA-590-3p (miR-590-3p) with PART1 or high mobility group box 2 (HMGB2) in HCC. Moreover, expression levels of PART1, miR-590-3p, and HMGB2 in HCC tissues and normal tissues were analyzed at ENCORI.

Results: PART1 expression was found to be significantly upregulated in HCC tissues and cells. Functionally, silencing of PART1 significantly suppressed HCC cell proliferation, colony formation and invasion in vitro, while forcing PART1 exerts opposite biological effects. Mechanically, miR-590-3p/HMGB2 axis was downstream target of PART1, and silencing of miR-590-3p or forcing of HMGB2 could rescue the stimulation effects of PART1 overexpression on HCC cell behaviors.

Discussion: Our results provided evidence that PART1 serves as oncogenic lncRNA through sponging miR-590-3p to upregulate HMGB2 expression in HCC.

Keywords: PART1, miR-590-3p, HMGB2, ceRNA, hepatocellular carcinoma

Introduction

Hepatocellular carcinoma (HCC) is the main subtype of liver cancer with a poor prognosis. The infection of hepatitis B virus (HBV) is the main cause for the development of HCC. The long-term overall survival of HCC remains undesired even with the recent appearance of tumor targeted therapeutic agents.

Long noncoding RNA (lncRNA) is a type of noncoding RNA with the length of over 200 nucleotides. The importance of lncRNA in regulating multiple cancer progressions including HCC has been recognized. Hence, investigating acting mechanisms of lncRNAs in HCC could provide novel therapeutic targets for HCC.

PART1, located at chromosome 5q12 60,487,713–60,547,657, is a lncRNA that is firstly identified to be overexpressed in prostate cancer. Liu et al showed that high PART1 level was closely correlated with prognosis of laryngeal squamous cell...
carcinoma cancer patients and could be used as prognostic biomarkers and therapeutic targets.\textsuperscript{9} Hu et al revealed \textit{PART1} was overexpressed in bladder cancer, and silencing of \textit{PART1} inhibits cancer cell growth through promoting apoptosis.\textsuperscript{10} Recently, Zhu et al investigated the functions of \textit{PART1} in non-small-cell lung cancer and found \textit{PART1} could promote cancer development via regulating Janus kinase and signal transducer and activator of transcription proteins pathway.\textsuperscript{11} A recent study indicated that \textit{PART1} could be used as a predictor for overall survival and recurrence-free survival of HCC patients.\textsuperscript{12} However, biological roles and underlying mechanisms of \textit{PART1} in HCC remain poorly investigated.

High mobility group box 2 (\textit{HMGB2}) is found highly expressed in cancers and functions as an oncogene.\textsuperscript{13–15} For instance, \textit{HMGB2} could regulate gastric cancer progression under the regulation of IncRNA and miRNA.\textsuperscript{13,14} Also, there are several targets for \textit{HMGB2} including \textit{LDH}B and \textit{FBP}1 have been found in cancers.\textsuperscript{15}

This work was conducted to investigate the roles of \textit{PART1} in HCC by analyzing how it influences cancer hallmarks. We also investigate miRNA between \textit{PART1} and \textit{HMGB2} to understand the mechanisms of \textit{PART1} in HCC.

\section*{Materials and Methods}

\subsection*{Cell Culture}

HCC cells (SMMC-7721 and Huh7) and normal hepatic cell line LO2 were purchased from Cell Bank of Chinese Academy Sciences. Cells were cultured with DMEM supplemented with 10% FBS (Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a 37°C humidified incubator contains 5% CO\textsubscript{2}.

\subsection*{Cell Transfection}

Small interfering RNA against \textit{PART1} (\textit{si-PART1}, 5'-GCAAUGAAAGCUACCAGAU-3'), against \textit{HMGB2} (\textit{si-HMGB2}, 5'-AAGACCAUGUGCAAGAG-3'), negative control (\textit{si-NC}, 5'-UUCCUCCGACGUGCACGUTT-3'), \textit{mir-590-3p} mimic (5'-UAAUUUUAUGUAAAGCUGU-3'), and matched negative control (\textit{mi-NC}, 5'-AUAAUGGUACGGAUUAUAUA-3') were purchased from GeneChem (Shanghai, China). pcDNA3.1 contains sequence of \textit{PART1} (\textit{pPART1}) was obtained from GenePharm. Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific, Inc.) was used for cell transfection.

\section*{Cell Proliferation Assay}

Cells were seeded into 96-well plate at density of 2×10\textsuperscript{3} cells/well and incubated for 0, 24, 48, and 72 h. Cell counting kit-8 (CCK-8) reagent (Beyotime, Haimen, Jiangsu, China) was added to the plate and further incubated for four hours. Optical density was observed at the wavelength of 450 nm using a microplate reader.

\section*{Colonie Formation Assay}

Six hundred cells were incubated in a six-well plate and allow to grow for 14 days. Colonies were fixed with methanol, stained with crystal violet, and counted under a microscope. Colony numbers were calculated using formula: colonies from five independent fields/5.

\section*{Transwell Invasion Assay}

We seeded 5×10\textsuperscript{4} cells in serum-free DMEM on upper chamber of Matrigel coated insert. The lower chamber was filled with DMEM containing FBS. After 24 h incubation, invaded cells were fixed with paraformaldehyde, stained with crystal violet, and washed with PBS. Invaded cell numbers were counted under an optical microscope.

\section*{Quantitative Real-time Polymerase Chain Reaction (RT-qPCR)}

TRizol reagent (Beyotime) was used to isolate RNA sample from cultured cells. Then, RNA was reverse transcribed into complementary DNA using PrimeScript RT kit (Takara, Dalian, Liaoning, China). RT-qPCR was conducted at ABI 7500 system (Foster City, CA, USA) using SYBR Green (Takara). Relative gene expression level was calculated with 2−ΔΔCt method. Primers used were: \textit{PART1}: 5'-AAGGCCGTGTCAGAACTCAA-3' (forward) and 5'-GTGTTCCTATCTCAAGGTCGA-3' (reverse); \textit{HMGB2}: 5'-GGGAAAAAGGACCCCA-3' (forward) and 5'-GCTGACTGCTCACAGGACAT-3' (reverse); \textit{GAPDH}: 5'-AACGCTGTAAGTGGTGGACCTG-3' (forward) and 5'-AGTGGGTGTCGCTGTTGAAGT-3' (reverse); \textit{miR}-590-3p: 5'-GCAGTAATTTTATGTATAA-3' (forward) and 5'-GTCGACGGTCCCGAGG-3' (reverse); \textit{U6} snRNA: 5'-CCTCGCTGCGAGAATTC-3' (forward) and 5'-AACGCTTCACGAAATTTGCCG-3' (reverse).

\section*{Immunoblotting Assay}

Total proteins from cells were extracted using RIPA lysis buffer (Beyotime) and quantified with BCA kit (Beyotime). Twenty-five micrograms of protein sample
was separated at 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis and transferred to PVDF membrane. Then the membrane was incubated with primary antibodies (anti-HMG2: ab124670, anti-GAPDH: ab181602, Abcam, Cambridge, MA, USA). PVDF membrane was further incubated with horseradish peroxidase-conjugated secondary antibodies (ab6721, Abcam). Band signal was detected with BeyoECL kit (Beyotime).

Targets Prediction Using Bioinformatic Tool
miRNA target for PART1 was analyzed at LncBase V 2.0. Target gene for miRNA was analyzed at TargetScan. miR-590-3p and HMG2 were selected for further analysis using these two bioinformatic tools.

Luciferase Reporter Assay
pmiR-Report luciferase vector contains wild-type (wt) sequence of PART1 or HMG2 was named as wt-PART1/HMG2. Mutant luciferase vectors were constructed using site-direct mutagenesis kit (Takara) and named as mt-PART1/HMG2. Cells were transfected with luciferase reporter vectors and miRNAs using Lipofectamine 2000. After 48 h transfection, relative luciferase activity was measured using Dual-luciferase reporter assay kit (Promega, Madison, WI, USA).

Expression Level of PART1, miR-590-3p, and HMG2 in HCC Tissues Was Detected at ENCORI
Expression levels of PART1, miR-590-3p, and HMG2 in HCC tissues and normal tissues were analyzed at ENCORI website.

Silencing of PART1 Hinders HCC Progression
BALB/c nude mice were used to detect the roles of PART1 on HCC progression in vivo. Study protocol was approved by the Ethics Committee of Affiliated Hospital of Youjiang Medical University for Nationalities and performed in accordance with National Guidelines for Experimental Animal Welfare issued by the Ministry of Science and Technology, China. Cells transfected with PART1 knockdown (sh-PART1 (5’-ACCTCATGCAGCT TGACTGTGATTCAAGAGTGAAATCACAGTCAAGTGCAATT-3’) or sh-NC (5’-ACCTCATGCAGCT GCCTCTAATTCAGAGATTAAAGCCGCAAATCG- TACTT-3’)) or stable PART1 overexpression were injected into the flank of nude mice. Tumor width and length were measured every seven days to calculate tumor volume. After four weeks, the mice were killed to measure tumor weight. Furthermore, RNA samples were extracted from these tissues to measure the relative gene expression level.

Statistical Analysis
GraphPad Prism 8.0 (GraphPad Inc., San Diego, CA, USA) was used to analyze data obtained from three independent experiments. Differences were calculated using one-way ANOVA and Tukey’s post hoc test or Student’s t-test. Data were presented as mean ± SD. P-value < 0.05 was an indicator for significant difference.

Results
PART1 Expression was Elevated in HCC
ENCORI analysis showed PART1 was significantly elevated in HCC tissues compared with normal tissues (Figure 1A). Moreover, RT-qPCR analysis result demonstrated PART1 was upregulated in HCC cells in comparison with normal cells (Figure 1B).

Knockdown of PART1 Suppresses HCC Cell Proliferation, Colony Formation, and Migration
Introduction of si-PART1 significantly decreased PART1 expression in HCC cells (Figure 2A). CCK-8 assay revealed knockdown of PART1 inhibits HCC cell proliferation rate (Figure 2B). Colony formation assay confirmed the results of CCK-8 assay (Figure 2C). Moreover, decreased invasion ability was observed in HCC cells with si-PART1 transfection (Figure 2D).

Overexpression of PART1 Promotes HCC Cell Proliferation, Colony Formation, and Migration
In addition, gain-of-function experiments were conducted to investigate the roles of PART1. Transfection of pPART1 significantly increased the levels of PART1 in HCC cells (Figure 3A). CCK-8 and colony formation assays confirmed PART1 overexpression promotes HCC cell growth (Figure 3B and C). Moreover, invasive cell numbers were significantly increased after PART1 overexpression (Figure 3D).
Figure 1 Expression of PART1 in HCC. (A) Expression of PART1 in HCC tissues and normal tissues. (B) Expression of PART1 in HCC cell lines and normal cell line. \* \( P<0.001 \). PART1: prostate androgen-regulated transcript 1.

Abbreviation: HCC, hepatocellular carcinoma.

Figure 2 PART1 knockdown inhibits HCC cell proliferation, colony formation and invasion. (A) Transfection efficacy of si-PART1 and si-NC in HCC cells. (B) CCK-8 assay revealed HCC cell proliferation was suppressed by PART1 knockdown. (C) Colony numbers were reduced by PART1 knockdown in HCC cells. (D) Transwell invasion assay found that PART1 knockdown suppressed invasion of HCC cells. \* \( P<0.001 \), \** \( P<0.01 \).

Abbreviations: PART1, prostate androgen-regulated transcript 1; HCC, hepatocellular carcinoma; si-PART1, small interfering RNA targeting PART1; si-NC, negative control siRNA; CCK-8, cell counting kit-8.
**PART1** Regulates miR-590-3p and **HMGB2** in HCC

Growing evidence indicated **PART1** serves as competing endogenous RNA (ceRNA) to sequester miRNA and regulate target gene expression.\textsuperscript{10,11} miR-590-3p was revealed to be the potential target for **PART1** (Figure 4A). miR-590-3p level was found to be decreased in tumor tissues compared with normal tissues (Figure 4B). Moreover, the knockdown of **PART1** significantly increased miR-590-3p levels in HCC cells (Figure 4C). Importantly, forcing miR-590-3p expression reduced relative luciferase activity of HCC cells transfected with wt-**PART1** but not mt-**PART1** (Figure 4D). Moreover, miR-590-3p was found to bind with **HMGB2** through TargetScan analysis (Figure 4E). **HMGB2** level was found to be elevated in HCC tissues compared with normal tissues (Figure 4F). Interestingly, transfection of miR-590-3p mimic decreased **HMGB2** mRNA levels in HCC cells (Figure 4G). Western blot confirmed that forcing miR-590-3p expression decreased **HMGB2** protein levels in HCC cells (Figure 4H). As expected, forcing miR-590-3p expression inhibited relative luciferase activity of HCC cells transfected with wt-**HMGB2** (Figure 4I).

**miR-590-3p and **HMGB2** Mediates the Oncogenic Role of **PART1** in HCC**

To further explore the roles of miR-590-3p and **HMGB2** in HCC, rescue experiments were conducted. RT-qPCR showed overexpression of miR-590-3p or knockdown of **HMGB2** partially reversed the effects of p**PART1** on **HMGB2** expression (Figure 5A). CCK-8 assay, colony formation assay, and transwell invasion assay indicated that the stimulation effects of p**PART1** on HCC cells could be abrogated by miR-590-3p overexpression or **HMGB2** knockdown (Figure 5B–D).

---

**Figure 3** **PART1** overexpression promotes HCC cell proliferation, colony formation and invasion. (A) Transfection efficacy of p**PART1** and pcDNA3.1 in HCC cells. (B) CCK-8 assay revealed HCC cell proliferation was stimulated by p**PART1** overexpression. (C) Colony numbers were increased by p**PART1** overexpression in HCC cells. (D) Transwell invasion assay found that p**PART1** overexpression promoted invasion of HCC cells. *P<0.001, **P<0.01.

**Abbreviations:** **PART1**, prostate androgen-regulated transcript 1; HCC, hepatocellular carcinoma; CCK-8, cell counting kit-8.
Roles of PART1 on HCC Tumor Growth in vivo

To analyze the roles of PART1 in vivo, cells with PART1 knockdown or overexpression were used to establish xenograft model. The results in Figure 6A and B showed that both tumor volume and tumor weight were decreased by sh-PART1 compared with sh-NC. On the contrary, tumor volume and weight were increased after HMGB2 overexpression (Figure 6A and B). Furthermore, we showed the expression of PART1 and HMGB2 was significantly decreased by PART1 knockdown, while increased by PART1 overexpression (Figure 6C). Moreover, the expression of miR-590-3p was dramatically increased by PART1 knockdown and decreased by PART1 overexpression (Figure 6C).
Growing evidence indicated lncRNAs played crucial roles in regulating HCC progression.\(^{16,17}\) lncRNA activated by transforming growth factor beta was revealed as a predictor for poorer overall survival of HCC patients, and regulated HCC cell autophagy via activating Yes-associated protein and autophagy-related protein five expression.\(^{16}\) Moreover, a recent study showed small nucleolar RNA host gene 7 (SNHG7) increased expression in HCC tissues compared with those in normal tissues.\(^{17}\) Mechanism studies showed SNHG7 could promote HCC tumorigenesis via sponging miR-122-5p to upregulate ribosomal protein L4 expression.\(^{16}\)

In this study, our RT-qPCR data and ENCORI analysis data showed PART1 was highly expressed in HCC cells and tissues. Moreover, silencing of PART1 could inhibit HCC cell growth and invasion. Importantly, forcing of PART1 could promote HCC cell growth and invasion. In vivo analyses indicated that silencing of PART1 could suppress tumor growth, while forcing of PART1 exerts opposite effects on tumor growth. These results collectively may suggest the oncogenic role of PART1 in HCC,
a role that was reported in previous studies.\textsuperscript{10,11} A very recent study conducted by Zhou et al indicated \textit{PART1} could boost HCC progression via the miR-149-5p/MAP2K1 pair in vitro.\textsuperscript{18} Our work can be regarded as another proof for the oncogenic role of \textit{PART1} in HCC. However, there is a difference between our current work and this work, which is that we provided in vivo analysis results to support the oncogenic role of \textit{PART1}.

It has been widely recognized lncRNA exerts biological roles via regulating miRNA and target gene. We found miR-590-3p, downregulated expression in HCC, was a putative target for \textit{PART1}. We confirmed the direct interaction of \textit{PART1} and miR-590-3p through luciferase activity reporter assay, miR-590-3p was reported to function as either tumor promoter or suppressor gene in cancers.\textsuperscript{19,20} Considering the distinct role of miR-590-3p in cancers, hence the roles of miR-590-3p in HCC was explored. We validated the interaction of miR-590-3p and \textit{HMGB2}. \textit{HMGB2} was reported to function as an oncogene in cancers.\textsuperscript{12–14} In our work, we also found \textit{HMGB2} expression was elevated in HCC tissues and cells. Importantly, miR-590-3p overexpression or \textit{HMGB2} knockdown partially reversed \textit{PART1} overexpression on HCC cell proliferation, colony formation and invasion. The limitation of this work is that we did not explore the expression levels of this newly identified ceRNA triplet in HCC clinical samples. In addition, the clinical significance of these genes in HCC was not investigated. Hence,
further experiments are still needed to validate the importance of this PART1/miR-590-3p/HMGB2 axis in HCC.

Conclusion
To conclude, our work provided evidence that PART1 was elevated expression in HCC. In vitro and in vivo assays revealed PART1 could promote HCC tumor progression by regulating miR-590-3p/HMGB2. Our work provided novel evidence regarding mechanisms underlying HCC pathogenesis.

Author Contributions
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding
This work was supported by Science and Technology Project (AD17129025).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
3. Waidmann O. Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2018;18(8):905–910. doi:10.1080/14712598.2018.1499722
4. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. doi:10.1038/nrg.2015.10
5. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463. doi:10.1016/j.ccell.2016.03.010
6. Li C, Chen J, Zhang K, Feng B, Wang R, Chen L. Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma. Cell Physiol Biochem. 2015;36(2):423–434. doi:10.1159/00040109
7. Wang B, Tang D, Zhang Z, Wang Z. Identification of aberrantly expressed lncRNA and the associated TF-mRNA network in hepatocellular carcinoma. J Cell Biochem. 2019. doi:10.1002/jcb.29384.
8. Lin B, White JT, Ferguson C, et al. PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res. 2000;60(4):858–863.
9. Liu Y, Ye F. Construction and integrated analysis of crosstalkning ceRNAs networks in laryngeal squamous cell carcinoma. Peer J. 2017;7:e7380. doi:10.7717/peerj.7380
10. Hu X, Feng H, Huang H, et al. Downregulated long noncoding RNA PART1 inhibits proliferation and promotes apoptosis in bladder cancer. Technol Cancer Res Treat. 2019;18:1533033819846638. doi:10.1177/1533033819846638
11. Zhu D, Yu Y, Wang W, et al. Long noncoding RNA PART1 promotes progression of non-small cell lung cancer cells via JAK-STAT signaling pathway. Cancer Med. 2019;8(13):6064–6081. doi:10.1002/cam4.2494
12. Ye J, Zhang J, Lv Y, et al. Integrated analysis of a competing endogenous RNA network reveals key long noncoding RNAs as potential prognostic biomarkers for hepatocellular carcinoma. J Cell Biochem. 2019;120(8):13810–13825. doi:10.1002/jcb.28655
13. Cui G, Cai F, Ding Z, Gao L. HMGB2 promotes the malignancy of human gastric cancer and indicates poor survival outcome. Hum Pathol. 2019;84:133–141. doi:10.1016/j.humpath.2018.09.017
14. Xu CH, Xiao LM, Liu Y, et al. The lncRNA HOXA11-AS promotes glioma cell growth and metastasis by targeting miR-130a-5p/ HMGB2. Eur Rev Med Pharmacol Sci. 2019;23(1):241–252. doi:10.26355/eurrev.201901.16770
15. Fu D, Li J, Wei J, et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell Commun Signal. 2018;16(1):8. doi:10.1186/s12983-018-0219-0
16. Wang CZ, Yan GX, Dong DS, Xin H, Liu ZY. LncRNA-ATB promotes autophagy by activating Yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 2019;25(35):5310–5322. doi:10.3748/wjg.v25.i35.5310
17. Yang X, Sun L, Wang L, Yao B, Mo H, Yang W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomed Pharmacother. 2019;118:109386. doi:10.1016/j.biopha.2019.109386
18. Zhou C, Wang P, Tu M, Huang Y, Xiong F, Wu Y. Long non-coding RNA PART1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells via miR-149-5p/MAP2K1 axis. Cancer Manag Res. 2020;12:3771–3782. doi:10.2147/CMAR.S246311
19. Feng ZY, Xu XH, Cen DZ, Luo CY, Wu SB. miR-590-3p promotes colon cancer cell proliferation via Wnt/β-catenin signaling pathway by inhibiting WIFI and DKK1. Eur Rev Med Pharmacol Sci. 2017;21(21):4844–4852.
20. Zu C, Liu S, Cao W, et al. MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression. Oncotarget. 2017;8(21):34698–34708. doi:10.18632/oncotarget.16150